Beyond the looking glass: recent advances in understanding the impact of environmental exposures on neuropsychiatric disease by Hollander, Jonathan A. et al.
REVIEW ARTICLE OPEN
Beyond the looking glass: recent advances in understanding the
impact of environmental exposures on neuropsychiatric disease
Jonathan A. Hollander1, Deborah A. Cory-Slechta2, Felice N. Jacka 3,4,5,6,7, Steven T. Szabo8,9, Tomás R. Guilarte10, Staci D. Bilbo11,
Carolyn J. Mattingly12, Sheryl S. Moy13, Ebrahim Haroon 14, Mady Hornig 15, Edward D. Levin 16, Mikhail V. Pletnikov17,
Julia L. Zehr18, Kimberly A. McAllister1, Anika L. Dzierlenga1, Amanda E. Garton1, Cindy P. Lawler1 and Christine Ladd-Acosta19
The etiologic pathways leading to neuropsychiatric diseases remain poorly defined. As genomic technologies have advanced over
the past several decades, considerable progress has been made linking neuropsychiatric disorders to genetic underpinnings.
Interest and consideration of nongenetic risk factors (e.g., lead exposure and schizophrenia) have, in contrast, lagged behind
heritable frameworks of explanation. Thus, the association of neuropsychiatric illness to environmental chemical exposure, and
their potential interactions with genetic susceptibility, are largely unexplored. In this review, we describe emerging approaches for
considering the impact of chemical risk factors acting alone and in concert with genetic risk, and point to the potential role of
epigenetics in mediating exposure effects on transcription of genes implicated in mental disorders. We highlight recent examples
of research in nongenetic risk factors in psychiatric disorders that point to potential shared biological mechanisms—synaptic
dysfunction, immune alterations, and gut–brain interactions. We outline new tools and resources that can be harnessed for the
study of environmental factors in psychiatric disorders. These tools, combined with emerging experimental evidence, suggest that
there is a need to broadly incorporate environmental exposures in psychiatric research, with the ultimate goal of identifying
modifiable risk factors and informing new treatment strategies for neuropsychiatric disease.
Neuropsychopharmacology (2020) 45:1086–1096; https://doi.org/10.1038/s41386-020-0648-5
INTRODUCTION
Neuropsychiatric conditions such as anxiety, major depression,
bipolar disorder, schizophrenia, obsessive-compulsive disorder,
autism spectrum disorder (ASD), attention-deficit/hyperactivity
disorder (ADHD), and post-traumatic stress disorder affect
hundreds of millions of people worldwide. The economic and
social costs are substantial [1, 2]. While much progress has been
made in identifying the complex genetic contributions to these
disorders [3], genetics alone does not fully explain risk and there is
significant variation that can be ascribed to environmental factors.
In the broadest sense, environmental exposures can be viewed as
nongenetic factors that include psychosocial factors, diet and
nutrition, pharmaceuticals and medical interventions, health
conditions, infectious agents, environmental chemicals, and
physical features of the environment. The contribution of some
of these broadly defined factors, such as drugs of abuse and
developmental risk factors (e.g., preterm birth and early-life
adversity), to the pathogenesis of neuropsychiatric abnormalities
have been well-studied (and discussed elsewhere) [4–7] compared
to non-pharmaceutical chemicals that individuals are exposed to
such as pesticides, metals, and air pollutants. In some cases, work
in model systems has facilitated exploration of how environmental
perturbations impact brain processes relevant to mental health.
Such studies have furthered our understanding of vulnerability to
neuropsychiatric disorders and revealed factors contributing to
resiliency. Detailed investigation of the mechanisms and comor-
bidities associated with the development of neuropsychiatric
disorders after exposure to environmental contaminants offers the
potential to afford similar gains.
Emerging evidence has suggested that exposures to environ-
mental chemicals can contribute to the pathogenesis of
neuropsychiatric abnormalities. One of the few historical examples
comes from occupational exposure to mercurous nitrate in the
process for curing felt for the production of hats [8]. Prolonged
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mercury exposure led to “Mad Hatter” syndrome with symp-
toms including depression, delirium, and tremor [9, 10]. Other
evidence comes from studies of lead (Pb), a prevalent exposure
risk that has been known for many decades to cause cognitive
impairments, even at low levels [11]. Indeed, for children, the US
Centers for Disease Control and Prevention (CDC) currently
maintains that “no safe blood lead level…has been identified”
(https://www.cdc.gov/nceh/lead/default.htm). Pb exposures in
childhood have been associated with specific neuropsychiatric
disturbances, including symptoms of ADHD, anxiety, and depres-
sion [12–14]. A 17-year prospective birth cohort study in Chicago
reported that each 1 µg/dL increase in blood Pb was associated
with a 0.09 point increase in anxiety/depression symptom scores
[15]. Deficits in executive function, a hallmark of many neurop-
sychiatric disorders, have also been linked to developmental Pb
exposure in experimental systems [16]. Other studies have shown
that developmental exposure to pesticides is associated with
neuropsychiatric behavioral phenotypes [17, 18].
A deeper understanding of the risk of psychiatric disorders
related to environmental exposures and the underlying biological
mechanisms could lead to more effective prevention and
treatment. This review summarizes how genetic and environ-
mental factors, along with epigenetic modifications, are being
investigated to assess susceptibility and progression of neurop-
sychiatric disease. Next, three exemplar biological targets of
environmental exposures that may contribute to etiology of
mental health disorders—synaptic integrity and transmission,
immune function, and signaling along the gut microbiome-brain
axis are described. Finally, key challenges that remain to be
addressed to enable a rigorous interrogation of the potential
importance of environmental agents as determinants of risk for
the development of this diverse and heterogeneous constellation
of disorders are outlined.
THE IMPORTANCE OF INCLUDING GENETICS IN STUDIES THAT
ASSESS ENVIRONMENTAL RISKS FOR NEUROPSYCHIATRIC
DISORDERS
Most psychiatric illnesses are considered to be complex diseases
that involve genetic and environmental risk factors. Large
genome-wide association studies (GWAS), made possible through
the Psychiatric Genomics Consortium (https://www.med.unc.edu/
pgc/about-us), have identified common genetic risk variants
associated with specific psychiatric disorders [19–23], as well as
across psychiatric disorders [24]. Common genetic risk variants for
psychiatric outcomes are highly polygenic with many different
genetic variants each contributing a small risk effect [25, 26].
Complementary whole-exome and genome-based studies have
also identified a number of rare and/or de novo genetic variants
that have larger risk effects on psychiatric outcomes. It is clear that
genetic variation exerts a powerful influence on risk for major
neuropsychiatric disorders; however, evidence as to the strength
of these effects is conflicting. The wide variation in heritability
estimates across and within neuropsychiatric disorders [27–29],
and relatively small proportion of phenotypic variance explained
by the genetic variants discovered to date, leaves substantial
room for contributions from environmental factors in under-
standing neuropsychiatric risk.
The growing recognition that both genes and environmental
factors contribute to neuropsychiatric disease risk underscores the
need for studies that examine environmental exposures in the
context of genetic risks, e.g., via gene–environment interactions
(GxE). There are several conceptual models outlining how genes
and environment can interact to influence disease susceptibility
[30–34]; most neuropsychiatric studies have focused on the
diathesis–stress interaction model [35], which postulates that
inter-individual differences in genes result in different suscept-
ibilities to environmental risk factors and candidate genes.
Substance use disorders (SUDs) have been particularly prolifera-
tive in investigating GxE with numerous reports of interactions
between social adversity or stress exposure and genetic variants
that influence risk of drug or alcohol abuse [36–41]. Chemical
exposures-gene interactions that influence risk of psychiatric and
neurologic diseases have also been reported. For example,
individuals with increased air pollutant or heavy metal exposure
and a particular genetic variant have increased risk of neurode-
velopmental disorders compared to individuals without the
genetic variant, suggesting the genetic variant makes them more
susceptible to the chemical exposure [42–46]. Interaction between
cigarette smoking and genotype at the PON1 gene locus were
observed to influence the risk of bipolar and major depression
disorders [47]. Studies that assess chemical exposures and a wider
range of gene-environment conceptual models are needed to
advance our understanding of gene–environment interactions in
neuropsychiatric disease and better inform prevention, interven-
tion, and treatment efforts.
Integration of genetic and chemical exposure data offers new
opportunities in psychiatric research but there are numerous
challenges that need to be recognized and properly addressed in
GxE studies, including the need for large sample sizes, considera-
tion of exposure complexities and measurement error, potential
correlation between genetic and environmental factors, and use
of appropriate study designs and statistical methods [48].
Researchers are beginning to address and overcome several of
these challenges. First, studies based on unified genome-wide
genetic and exposure information in large samples are emerging
to facilitate the study of GxE in neuropsychiatric disorder
pathogenesis. One such study is the Initiative for Integrative
Psychiatric Research (iPSYCH), a consortium integrating data from
national registries and genomic analysis of neonatal blood spots
[49]. Many other large-scale studies, including work related to
efforts of the Nordic OCD & Related Disorders Consortium
(NORDiC), have been launched that will link genomic data with
nongenetic exposures as contributors to mental health [50, 51]. In
addition to launching new studies that collect both genetic and
environmental information, experimental designs that can lever-
age substantial extant genomics data and biorepository resources
would enhance GxE efforts. This will likely involve development of
new cost-effective methods to enable rigorous ascertainment of
environmental exposure data from individuals with extant genetic
data. Statistical challenges in GxE include low power for traditional
statistical methods and inconsistent results that have often failed
to replicate in independent samples for both candidate gene and
genome-wide GxE studies. Over the decade new statistical
methods have been developed to improve power, appropriately
control for type I error rates, address exposure misclassification
and gene–environment correlation, and to ensure efficient
implementation of GxE analyses [52, 53]. In addition, the recent
development of polygenic risk scores, representing an individual’s
genome-wide genetic risk as a single summed variable, provides
opportunities to evaluate environmental exposure risks in the
context of aggregate genetic risk using a well-powered approach.
Finally, there are several additional complexities related to
potential confounding and correlations between genetic and
environmental exposures in human observational studies. Expo-
sure mixtures and multiple forms of genetic risks (e.g., inherited
common single nucleotide polymorphisms, rare de novo variants,
DNA structural variants), need to be considered and potentially at
different developmental or life course stages. In addition, genetic
variation can result in different exposure to environmental risks.
For example, single nucleotide polymorphisms (SNPs) located
within the nicotinic receptor genes on chromosome 15 influence
smoking behaviors [54]. Importantly, correlations between
polygenic risk liability and environmental risk factors for
psychiatric health outcomes have been reported [55, 56]. Thus,
assessing gene-exposure correlations using unified genetic and
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environmental exposure data could provide important insights
into the contribution of each risk factor, and their potential
interplay, on psychiatric health outcomes. Complementary GxE
studies in animal and cellular models provide an opportunity to
overcome issues of confounding, timing, gene-exposure correla-
tion, and exposure mixtures that are present in human observa-
tional data because they use highly controlled experimental
conditions. Additionally, they can provide important mechanistic
insights not always possible in human observational research.
EPIGENETICS
Multiple lines of evidence support a role for epigenetics in the
etiology of psychiatric disorders, particularly for chromatin
remodeling and DNA methylation. Rare variant genetic studies
of autism spectrum and bipolar disorders have shown chromatin
remodeling genes are more frequently dysregulated among
affected individuals [57–60]. Integration of genetic and epigenetic
data has shown that genetic risk variants for ASD, schizophrenia,
ADHD, and bipolar disorder control DNA methylation levels more
often than non-psychiatric genetic variants [61–68]. Epigenetic
changes have also been directly observed in postmortem brain
[69–71], blood [72–74], semen [75, 76], saliva [77–79], placenta
[80], and buccal [81–83] tissues in individuals with a psychiatric
disorder. While these results support epigenetic involvement in
psychiatric disease, there is some debate about the validity and
reliability of these findings with respect to etiologic relevance. The
concerns mainly stem from the inaccessibility of mechanistically
relevant tissues or sorted cell types for brain disorders and the
timing of sample collection to ascertain whether epigenetic
changes are likely causal or consequential in the disease process.
Because of the practical difficulty with addressing some of these
concerns in human populations, complementary approaches
using in vitro and animal-based model research will be necessary.
Epigenetic changes have also been associated with a diverse set
of environmental exposures in human observational and animal
model studies, including for chemical toxicants; these have been
comprehensively reviewed elsewhere [84–88]. One of the best-
known examples of a chemical exposure that directly alters
epigenetic patterns comes from experiments in the Agouti mouse
model. Exposure to bisphenol-A (BPA) in these mice leads to shifts
in DNA methylation levels at the Agouti coat color locus and
ultimately, an altered coat color [89]. BPA has also been associated
with global and site-specific changes in DNA methylation and
histone tail modifications in human observational studies [90–92].
A cross-organism study found mouse liver DNA methylation levels
at the STAT3 locus were altered in response to perinatal exposure
to BPA and were also relevant to adult health outcomes [93]. The
authors also found similar DNA methylation changes in STAT3
related to BPA exposure levels measured in human fetal liver
samples. Epigenetic changes in response to BPA, a type of
endocrine disrupting chemical (EDC), are particularly relevant as
an example given reports that EDC exposure may increase risk of
psychiatric disease [94–96].
Studies of epigenetic changes related to chemical exposures
and psychiatric disease have mainly been performed in parallel.
Few studies have evaluated whether epigenetic changes related
to environmental exposures are also associated with psychiatric
disease or vice versa. Our ability to identify epigenetic changes
related to both environmental chemicals and psychiatric disease
and to formally evaluate potential epigenetic mechanisms in
environmental effects on mental health is limited by small
sample sizes, inaccessibility of brain tissue, potential exposure
mixtures and confounding, and a lack of large prospective
studies with unified epigenetic and environmental measures
from relevant risk windows. This will require new epidemiology
and animal and cellular model-system-based studies specifically
designed to overcome these limitations. The National Institute of
Environmental Health Sciences (NIEHS) is directly addressing
several of these challenges through the Toxicant Exposures and
Responses by Genomic and Epigenomic Regulators of Transcrip-
tion (TaRGET) II Program [97]. Even if epigenetic changes are not
in the causal pathway, they could provide a useful biomarker of
current and past environmental exposures, including prenatal
and early-life windows [98], or of psychiatric disease, which
would also have great utility.
Beyond genetic risks, gene–environment interactions and
epigenetic factors in psychiatric disorders, great progress has
been made in understanding neurobiological mechanisms. Three
examples of how environmental exposures may impact neuro-
biological substrates contributing to psychiatric disorders are
discussed, including impacts on synaptic biology in schizophrenia,
contributions of altered immune and microglial function to
neurodevelopment, and emerging research on the microbiome
and mood disorders. In each of these examples, environmental
exposures can interact in multiple ways to influence function that
contributes to risk for psychiatric disorders.
MODIFICATION OF SYNAPTIC TRANSMISSION BY
ENVIRONMENTAL EXPOSURE: EVIDENCE FROM STUDIES ON
LEAD AND SCHIZOPHRENIA
Perturbations in synaptic integrity, synaptic plasticity and neuro-
transmission are implicated in the pathophysiology of several
psychiatric disorders. Mice that lack actin depolymerizing proteins
(ADF) and n-cofilin, which are critical for synaptic function, showed
increases in locomotion and impulsive behaviors, as well as
impairments in working memory [99]. In addition, many neural
circuits require a balance between excitatory and inhibitory
neurotransmitters with new treatments for mood disorders
targeting modulation of gamma-aminobutyric acid (GABA) and
glutamate neurotransmission [100]. In this section, we will use
schizophrenia as an example to show the relevance of studying
synaptic mechanisms when considering potential targets of
environmental toxicants.
Aside from the longstanding dopamine hypothesis of schizo-
phrenia pathogenesis, altered glutamate and GABA neurotrans-
mission have also been implicated [101]. Substantial evidence
suggests that alterations in glutamatergic function can produce
changes in dopaminergic and GABAergic systems that may
underlie the positive and negative symptoms associated with
the cognitive components of the disease [102–104]. A currently
accepted pathophysiologic framework for schizophrenia relates to
hypofunction of the N-methyl-d-aspartate subtype (NMDAR) of
glutamatergic ionotropic receptor during critical periods of brain
development. This relative deficit in NMDARs results in alterations
of neurobiological processes essential for brain growth, wiring,
synaptic plasticity, and cognitive function, all of which are affected
in schizophrenia [105].
While a body of prior work has examined the association of
cannabis and tobacco smoking with schizophrenia risk, emerging
evidence points to a role for environmental Pb exposure. As
reviewed by Guilarte et al. [101], early-life Pb exposure in animals
recapitulates behavioral, neurobiological, and imaging changes
relevant to schizophrenia, including loss of parvalbumin-positive
GABAergic interneurons (PVGI) in the frontal cortex, hippocam-
pus, and striatum [106–108], and hyperactivity in the subcortical
dopaminergic system [109, 110]. A recent rodent study by
Stansfield et al. [111] found that chronic exposure to envir-
onmentally relevant concentrations of Pb (average 22 µg/dL)
during early brain development produced selective loss of the
PVGI phenotypic markers parvalbumin and glutamic acid
decarboxylase 67 (GAD67) in prefrontal cortex, hippocampus,
and striatum. Pb exposure also enhanced locomotor activity in
response to the psychostimulant cocaine and increased striatal
dopamine metabolites and D2-dopamine receptor binding,
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findings indicative of a hyperactive striatal dopaminergic system,
as seen in model systems and postmortem brain from individuals
with schizophrenia.
Population-based studies providing the first association of early-
life (prenatal) lead exposure and schizophrenia were described by
Opler and colleagues [112, 113]. Using two different population-
based cohorts, they found that prenatal lead exposure (maternal
blood lead levels estimated to be >15 μg/dL) were associated with
a significant increase in the risk of schizophrenia later in life.
Following these landmark studies there have been more recent
reports providing additional support to this association. For
example, a recent proof-of-concept study using childhood-shed
teeth and laser ablation inductively coupled plasma mass
spectrometry (LA-ICP-MS) showed higher levels of lead in teeth
from diagnosed schizophrenic subjects relative to controls [114].
Furthermore, they found a positive correlation between early-life
lead exposure and psychotic experiences in adulthood and a
negative correlation with adult IQ. One of the advantages of the
analysis of teeth using LA-ICP-MS is the ability to retrospectively
reconstruct environmental exposures from the second trimester of
pregnancy and through the first years of life. Using this approach,
they found that the negative correlation of lead exposure with IQ
was most pronounced if the exposure to lead occurred during the
prenatal period. Arinola and colleagues also found increased
plasma lead concentrations in newly diagnosed schizophrenic
subjects [115]. Another study using a multidecade longitudinal
design of lead-exposed children showed that higher levels of
blood lead were associated with greater psychopathology and
difficult personality traits as adults [116]. Childhood lead intoxica-
tion has also been associated with a high level of incarceration,
delinquent behavior, and substance abuse, which are comorbid
factors in schizophrenia [13, 117–119]. Lastly, recent assessments
on the burden of lead exposure as a risk factor for mental illness in
countries such as India have estimated that lead exposure
accounts for a large portion of the prevalence of mental disorders
including schizophrenia [120].
NEUROIMMUNE RESPONSES AND ENVIRONMENTAL
CHEMICALS
Immune perturbations have attracted special interest for their
possible link to psychiatric disorders [121–125], consistent with
emerging knowledge that cytokines, chemokines and other
immune factors, as well as the cells that produce them and/or
harbor cognate receptors for them within the brain, play
important roles in fetal brain development, brain maturation
and brain function in adulthood. Notably microglia, resident
immune cells of the brain, are critical players in normal brain
development. In turn, aberrant immune signaling early in life may
contribute to the pathogenesis of schizophrenia, ASD, and other
neuropsychiatric disorders. This is consistent with the idea that
early-life environmental exposures might affect later risk for
psychiatric disorders through effects on the immune system.
Research using maternal immune activation model(s) provides
some support for this general idea, as do studies of exposure to
chronic stress [126, 127]. Many chemical exposures are also known
to interact with immune pathways and molecules, or contribute to
the development of abnormal immune responses such as brain-
directed autoimmune reactions, yet the linkage to alterations in
brain development and the implications for psychiatric conditions
remain largely unexplored [128–131]. This section summarizes
recent work that points to microglia as an attractive target for
further studies to advance this line of inquiry.
Microglial development begins with colonization of the brain by
fetal yolk sac-derived macrophage precursor cells in early
embryonic stages, followed by migration and spread throughout
the central nervous system (CNS) [132, 133]. Microglia are critical
for normal brain development via the phagocytosis of extraneous
synapses [134–137] and apoptotic cells [138–140], learning-
dependent synapse formation [141, 142], cortical wiring [143],
neuronal survival [144], and the induction of programmed cell
death [139, 145]. Owing to the critical role that microglia play in
normal brain development, the activation or “programming” of
these dynamic, long-living cells in response to immune activation,
especially early in life, can have persistent consequences for brain
function throughout the lifespan [146]. Maternal immune activa-
tion (MIA) in mouse dams in response to a viral mimic,
Polyinosinic:polycytidylic acid (Poly IC), at GD 15 decreased
microglial phagocytic function and altered behavior consistent
with schizophrenia-like traits in humans, changes which were
reversed using a partial microglial inhibitor, minocycline [147].
These data point to a potential critical role for microglia in
persistent changes in neural function, although other studies have
failed to show an impact on microglial function in MIA models
[148]. This said, MIA models have typically been limited to
infectious stimuli, whereas MIA is likely elicited by a broader range
of environmental chemicals or stimuli, and we point to this
possibility briefly in the sections that follow.
Psychosocial stress is a well-studied nongenetic risk factor for
psychiatric disorders. Multiple stress models are associated with
features of microglial activation, highlighting the role of these cells
as key sensors of stress-related signaling by neurons [149].
Exposure to stress induces a chronically activated phenotypic
profile within microglia—referred to as “priming”—during which
time these cells undergo morphological changes, demonstrate
pro-inflammatory bias, and exhibit an exaggerated response to
experimental immune stimulation by endotoxins [150]. This
primed or “sensitized” profile of microglia in psychological stress
is implicated in the long-term re-establishment of behavioral
symptoms such as anxiety-like behaviors in mice initially exposed
to repeated social defeat stress [151].
There is now a significant body of literature linking air pollutant
exposures with microglial activation and other neuroimmune
changes, e.g., increased oxidative stress and lipid peroxidation
[152–154]. The association between ambient air pollution and
neurodevelopmental disorders such as ASD points to the prenatal
period as particularly important. Indeed, recent studies of air
pollution exposure underscore the ability of environmental
chemicals to impact brain development via effects on microglia
[155]. For example, maternal diesel exhaust particle (DEP)
exposure exerted sex-dependent effects on fetal brain microglial
morphology and development. Results in males were consistent
with activation and/or a delay in maturation in several brain
regions, along with striking changes in neural–glial interactions
suggestive of a defect in phagocytosis [156]. In addition, exposure
of pregnant dams to ultrafine particles (UFP), another component
of air pollution, leads to increases in corpus callosum size,
hypermyelination and microglial activation in offspring [157].
ENVIRONMENTAL EXPOSURES AND THE MICROBIOME-GUT-
BRAIN AXIS
The gut microbiome is increasingly understood to be a vital
contributing component of the gut-brain axis. Mechanisms by
which the microbiome may drive mental and brain health
outcomes, and the need to understand how environmental
chemicals can perturb these processes, are explored in this
section.
Microbes and microbial metabolites influence neurobehavioral
and neurotoxic outcomes through dysregulation of biological
signaling pathways, or disruption of epithelial barrier integrity
(“leaky gut”). Essential neurotransmitters for CNS functioning and
mood regulation are interdependent with functions of the gut
microbiome; for example, certain gut microbes are required to
support peripheral production of serotonin and GABA, with
serotonin serving as the key signaling molecule in both the
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enteric and central nervous systems [158, 159]. Critically, gut
microbiota and metabolites, including short chain fatty acids,
exert potent effects on peripheral immune processes via their
effects on intestinal epithelial cells and modulation of G-protein
coupled receptor-dependent signaling pathways [160]. In a leaky
gut state, intestinal microbe membrane-derived lipopolysacchar-
ide (LPS), also known as endotoxin, enters the peripheral
circulation to promote an inflammatory state. Persistent low-
grade immune-inflammatory processes have been implicated in
the pathophysiology of major depressive disorder (MDD), schizo-
phrenia, PTSD and mania [121, 122, 161–163], potentially linking
the gut microbiome to psychiatric outcomes.
The role of environmental chemical exposure in gastrointestinal
microbe–brain interactions is not well-characterized; however,
inferential evidence in the literature supports microbial dysbiosis
as a mediator of chemical-induced neurotoxicity. Toxicants may
factor into the aforementioned mechanisms by targeting specific
subpopulations of microbes to alter bacterial community diversity,
creating or enhancing a leaky gut or neuroimmune state, or by
undergoing biotransformation by bacteria to neurotoxic metabo-
lites. The potential role of the gut-brain axis in chemical-induced
neurotoxicity has been broadly reviewed previously [164, 165].
Despite the large body of literature pointing to interconnectivity
of the microbiome, chemical exposure, and the brain, few studies
have successfully linked all three factors in a manner that confers
causality. This may be due to the many challenges faced by
ascribing mechanism to something as variable as the microbiome.
Studies suggest that changes in intestinal microbiota diversity
and community may be associated with psychiatric disorders such
as ASD, schizophrenia, and depression [166–168]. While these
studies demonstrate a clear gut–brain interaction, they do not
consider the additional complexity of external environmental
factors. A wide range of environmental factors and neurological
outcomes have been linked to altered microbial composition. The
anti-seizure benefits of a ketogenic diet were found to be
dependent upon the microbiome in mice [169]. Light-stress in
mice led to enhanced abundances of some bacterial species and
metabolites, which correlated with reduced memory potential
[170]. Some studies have focused on chemical stressors as a
cause of microbial dysbiosis, although they tend to be more
correlative in nature; for example, neurobehavioral changes due to
developmental exposure to genistein, a phytoestrogen, were
correlated with microbiome and metabolome changes in Califor-
nia mice [171].
The most significant challenge faced in understanding the role
of the microbiome in psychiatric disorders, and human health
more broadly, is moving beyond association and correlation to
causation. This is not only true in rodents, but also in humans,
where it is less evident, which factor is the mediator for disease
and toxicity. Epidemiology studies have identified associations
between microbial dysbiosis and environmental exposure, includ-
ing traffic-related air pollution, persistent organic pollutants,
mercury, lead and other chemicals [165, 172–175]. It is necessary
to use a myriad of scientific approaches to arrive at a compelling
display of evidence for gut microbiome–brain interaction. There
have been several studies in rodents and humans examining this
interplay in ASD. In an animal model of ASD, gut permeability was
linked to serum levels of the microbial metabolite 4EPS; direct
treatment of 4EPS was sufficient to induce autism-like behaviors in
naïve mice [176]. Other studies have confirmed that autistic
behaviors in mouse models of ASD can be attenuated by
treatment with microbial metabolites or probiotics [177, 178]. A
fecal microbial transfer (FMT) study in germ-free mice showed that
mice harboring microbiota from human ASD donors, but not
typical donors, displayed hallmark autistic behaviors [177]. In
humans, there have been a few small studies assessing the utility
of the gut microbiome to alter behavior. FMT in children with ASD
who also presented with moderate gastrointestinal distress led to
gastrointestinal and behavioral improvements [179]. Much more
information is needed to understand which patient populations
are most responsive, and whether probiotic treatment would be a
valuable alternative. Importantly, there have also been many
environmental exposures associated with the development of
ASD [180–183], and more research into the role of the microbiome
could help elucidate mechanisms.
ASD is just one example of a psychiatric outcome that may sit at
the crossroads of microbial dysbiosis and environmental exposure.
Continuing to clarify the relationship among environmental
exposure, microbiome, and psychiatric outcomes is crucial
because of the potential impact on human health and preventa-
tive medicine. Understanding these nuances can pave the way for
developing novel interventions and biomarkers for exposure,
gaining insight into inter-individual susceptibility, and ultimately
allowing for focused, innovative, and holistic approaches to
medical treatment.
ADDRESSING KEY CHALLENGES
The previous sections highlighted three areas, synaptic biology,
immunology, and gut microbiome, where provocative new data
support the feasibility and significance of studies to identify the
role of environmental chemicals in psychiatric conditions. The
pace of continued progress will depend on the ability of
researchers to harness new tools and concepts that are being
developed to understand causation of complex disorders. Fore-
most is the development and implementation of the exposome
concept. Another important advance is the changing conceptua-
lization of psychiatric disorders; the field is moving from
symptom-based diagnosis to identifying patterns of neurobiologic
dysfunction and dimensional models of psychiatric traits. New
population-based preclinical models of common genetic diversity
and computational resources such as the Comparative Toxicoge-
nomics Database provide additional opportunities to explore
relationships among chemicals, genes, and psychiatric disorders.
This section lays out the promise of these new tools and
approaches for the study of environmental contributors to
psychiatric disorders.
Environmental health science is moving away from a focus on
single toxicants or single classes of exposure, recognizing that we
are exposed to complex mixtures that vary over time in
composition and intensity. The concept of the exposome,
proposed in 2005 as a complement to the genome [184], has
evolved to be defined as the “cumulative measure of environ-
mental influences and biologic responses throughout the lifespan”
[185]. Three broad and partially overlapping domains of the
exposome are recognized [186]. The specific external exposome
includes exposures such as environmental chemicals, pharmaceu-
ticals, radiation, infectious agents, diet and physical activity. The
general external exposome refers to larger social and economic
factors such as urbanicity, education, and climate. The internal
exposome comprises the chemical milieu within the body and
includes biologically active compounds associated with endogen-
ous processes (e.g., inflammation, metabolism, microbiome).
Significant advances in use and integration of data obtained from
geographic information systems, remote sensing, wearable
personal sensors, and numerous mobile phone-based applications
(e.g., activity tracking) have created new opportunities for
measuring important aspects of the external exposome [187].
Metabolomic-based biomonitoring has seen increasing use in
measuring the internal exposome, as it can provide an untargeted,
agnostic approach to characterize the holistic cellular response to
exposure(s) in the context of susceptibility factors (e.g., aging,
genetic variation). In the same way that genomic approaches
provide significant advantage over candidate gene approaches to
understanding the complex genetic architecture of psychiatric
disorders, exposomic approaches can deepen our knowledge of
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the multiple, interactive and time-dependent nongenetic factors
that affect risk and resilience for these disorders. While many
measurement and analytic challenges remain, meaningful pre-
paratory steps can be taken to ensure that psychiatric cohorts are
poised to capitalize on advances in exposomics [188–190].
Moreover, collaborative efforts between psychiatric and environ-
mental health researchers would provide an excellent testbed for
addressing the integration of different aspects of the external
exposome (e.g., environmental chemicals that are the focus of
environmental health science studies and larger social and
economic environments that are often considered in psychiatric
research).
The current phenomenological criteria used to clinically
diagnose an individual with mental illness is subjective [191],
leading to considerable variance and imprecision [192, 193]. For
research purposes, this means that individuals with distinct
neurobiological circuits and pathophysiology may be grouped
together under a single diagnosis, obscuring important differ-
ences in risk factors among individuals. The corollary, that two
individuals with different clinical diagnoses may have shared
pathophysiology, also creates challenges for clinical research. To
help address this issue, the National Institute of Mental Health
(NIMH) has spearheaded an initiative to classify neurocircuit
mediated symptoms, with relevance to psychiatric disorders, by
creating the Research Domain Criteria (RDoC) initiative [194, 195].
Although studies of environmental influences are strongly
emphasized and encouraged in RDoC research (https://www.
nimh.nih.gov/research/research-funded-by-nimh/rdoc/constructs/
rdoc-matrix.shtml), specific environmental effects are not listed
explicitly. New partnerships between psychiatric and environ-
mental health researchers are needed to implement RDoC for the
study of nongenetic/environmental influences. Psychiatric
researchers who are already collecting data in the framework of
RDoC domains and constructs can expand their studies to include
one or more exposures, thus contributing data to illuminate
whether and how relationships among functional domains and
constructs may depend on environmental context. Environmental
health researchers can consider how the RDoC framework can be
incorporated in their own lines of research; this may require
additional collection of physiology, behavior, cognition, and
symptom measures to enable systematic mapping to existing
RDoC domains and constructs. Ultimately, the use of objective
measures anchored to neurocircuits of neuropsychopathology as
in RDoC will allow for more precise evaluation of environmental
contributions to psychiatric symptoms and disease.
The increasing recognition of psychiatric disorders as dimen-
sional rather that dichotomous [196–199] also has implications for
the study of nongenetic influences. The low prevalence of most
psychiatric disorders requires very large sample sizes for
sufficiently powered population-based studies. Unfortunately,
deep and rigorous exposure assessments on large numbers of
study participants are often not feasible; however, if psychiatric
traits are distributed continuously in the general population, it is
possible to use an unselected sample to identify associations of
exposures with variation in the trait because, in addition to
individuals that meet diagnostic criteria, the much larger number
of individuals in the population-based sampling frame with
subclinical traits can contribute to identifying any association
with exposure. This approach could be adapted for use in many
existing smaller studies that have deep exposure characterization.
The Epidemiology Resources web tool (https://tools.niehs.nih.gov/
cohorts/) organizes and shares information about environmental
epidemiology studies supported by the NIEHS, with the goal of
facilitating new collaborations and ancillary studies such as those
recommended in this section.
Model systems provide a critical tool in the investigation of
environmental exposure effects on human health. Although
rodents cannot fully recapitulate the complex neuropathology of
psychiatric disorders, model systems can be used to test
hypotheses about the impact of perturbations representing
potential risk factors, including genomic or environmental
variables, on brain processes relevant to mental health. Thus,
these models can provide a platform to investigate the role of
environmental mechanisms that shape neurodevelopment of
circuits linked to etiology and symptomatology of human
psychopathology. Although models that focus on a single
exposure and/or genetic risk are prevalent, a promising trend is
the use of models that better reflect multifactorial risk. “Two-hit”
rodent models have been used to understand the interactions
between multiple or repeated exposures at critical developmental
timepoints. For example, a second juvenile exposure to poly-
chlorinated biphenyls (PCBs) can have profound and differential
sex-specific effects on gene expression, social or anxiety behavior
in rats prenatally exposed to the same PCBs [200, 201]. Many other
“two-hit” models, often focused on immune and/or stress
exposures, support the important role of combined exposures in
psychiatric phenotypes [202–204].
As was described in an earlier section, both rare and common
forms of genetic risk contribute to psychiatric disorders. A recent
GWAS study identified more than 100 genetic loci for schizo-
phrenia [21]. The large number of common alleles confer modest
effect; this suggests that reliance on models with disruption of
single genes to test gene–environment interaction may not be
informative. To confront the challenge of polygenic causation of
complex diseases, population-based mouse models have been
developed [205]. The Collaborative Cross (CC) is a large panel of
recombinant inbred mouse strains intentionally designed to
mimic the genetic diversity observed in human populations
[206, 207]; this provides a powerful model to support systems
genetic approaches for the study of quantitative biologic and
behavioral traits. In the context of environmental exposures,
studies using population-based mouse resources such as CC have
the advantage of including both mice with increased sensitivity
and those with reduced sensitivity (resilience). CC mice can be
used to study gene–environment interaction, i.e., how common
genetic variation modifies the effect of exposure(s) on psychiatric
phenotypes. As these mice capture a very wide range of common
genetic variation, researchers are freed from focusing on a
preselected small number of candidate genes/loci thought to
confer susceptibility, making it more likely that new, previously
unrecognized GxE will be identified. Two recent examples in
psychiatric research support the use of CC mice to study
gene–environment interactions [208, 209].
As emphasized throughout this section, new approaches are
needed to move beyond single gene and single exposure studies
of mental illness. Data generation is increasing in areas of brain-
based disorders, and spans genomics, transcriptomics, metage-
nomics, and exposomics. Given the diversity of information scope
and scale, providing resources to mine, share and manage
relevant information will require public resources and data
standards. One resource that merits attention is the Comparative
Toxicogenomics Database (CTD) [210]. CTD is a manually curated
database that provides information describing chemical-gene
interactions, chemical- and gene-disease relationships, chemical-
phenotype relationships and detailed exposure data [211–214].
These data are integrated with pathway and functional informa-
tion with tools that can help users inform hypotheses about the
etiologies of phenotypes and diseases with a specific focus on
environmental and exposure influences. In addition to curation
and summation of data providing direct evidence for linkage of a
gene or exposure with a disease, CTD provides statistically ranked
inferred relationships among genes, exposures and diseases. This
feature is particularly powerful for unearthing new clues about
possible chemical-disease relationships. For example, if the
curated literature indicates that an exposure influences the
expression of a gene and, in separate publications, that gene is
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associated with a disease, then CTD provides an inference (via the
shared gene) that the exposure is linked to the disease; this
provides a new testable hypothesis that can be pursued further in
laboratory or clinical settings. CTD has been employed in the
analysis of a range of brain disorders [215–218] and can be helpful
for guiding future hypotheses about relationships among
exposures, genes and psychiatric disorders.
CONCLUDING PERSPECTIVE
The landscape of psychiatric research has changed rapidly over
the past decade. The growing evidence that environmental
exposures disrupt normal brain and behavioral function to
increase psychiatric risk suggests that greater collaboration
between psychiatric and environmental health research commu-
nities is critical. Further, strategies to determine the most
appropriate and productive directions in psychiatric research will
undoubtedly require the inclusion of and appreciation for
emerging areas discussed here, e.g., synaptic plasticity, immunol-
ogy, gut microbiome-brain signaling, and others. The potential
payoff for identifying environmental risk factors for psychiatric
disorders is tremendous, as it affords a unique opportunity to not
just modify symptom trajectory following diagnosis, but the
possibility to prevent the development of the disease from the
outset.
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